drugset / Trial / NCT06016387
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Phase 2
Recruiting
30 enrolled
Sunnybrook Health Sciences Centre
Biocon Biologics Inc. · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The proposed study will evaluate the safety and efficacy of XRT followed by systemic therapy among patients with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer and LMD
Timeline
- Start
- 2023-11-25
- Primary completion
- 2026-12-31
- Completion
- 2028-10-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Tucatinib | Small molecule | 150 mg | — |